Cargando…
Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
BACKGROUND: Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated. METHODS: We exome sequenced 240...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923508/ https://www.ncbi.nlm.nih.gov/pubmed/33648514 http://dx.doi.org/10.1186/s12920-021-00902-5 |
_version_ | 1783658917322031104 |
---|---|
author | Beil, Adelyn Hornsby, Whitney Uhlmann, Wendy R. Aatre, Rajani Arscott, Patricia Wolford, Brooke Eagle, Kim A. Yang, Bo McNamara, Jennifer Willer, Cristen Roberts, J. Scott |
author_facet | Beil, Adelyn Hornsby, Whitney Uhlmann, Wendy R. Aatre, Rajani Arscott, Patricia Wolford, Brooke Eagle, Kim A. Yang, Bo McNamara, Jennifer Willer, Cristen Roberts, J. Scott |
author_sort | Beil, Adelyn |
collection | PubMed |
description | BACKGROUND: Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated. METHODS: We exome sequenced 240 cases with thoracic aortic dissection and 258 controls, then examined 11 aortopathy genes. Pathogenic variants in 6 aortopathy genes (COL3A1, FBN1, LOX, PRKG1, SMAD3, and TGFBR2) were identified in 26 participants, representing 10.8% of the cohort (26/240). A second research sample was used to validate the initial findings. Mailed letters to participants disclosed that a potentially disease causing DNA alteration had been identified (neither the gene nor variant was disclosed). Participants were offered clinical genetic counseling and confirmatory genetic testing in a CLIA laboratory. RESULTS: Excluding 6 participants who were deceased or lost to follow-up, 20 participants received the disclosure letter, 10 of whom proceeded with genetic counseling, confirmatory genetic testing, and enrolled in a survey study. Participants reported satisfaction with the letter (4.2 ± 0.7) and genetic counseling (4.4 ± 0.4; [out of 5, respectively]). The psychosocial impact was characterized by low decisional regret (11.5 ± 11.6) and distress (16.0 ± 4.2, [out of 100, respectively]). The average cost for 26 participants was $400, including validation and sending letters. The average cost for those who received genetic counseling and CLIA laboratory confirmation was $605. CONCLUSIONS: Participants were satisfied with the return of clinically significant biobank genetic results and CLIA laboratory testing; however, the process required significant time and resources. These findings illustrate the trade-offs involved for researchers considering returning research genetic results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-021-00902-5. |
format | Online Article Text |
id | pubmed-7923508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79235082021-03-02 Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants Beil, Adelyn Hornsby, Whitney Uhlmann, Wendy R. Aatre, Rajani Arscott, Patricia Wolford, Brooke Eagle, Kim A. Yang, Bo McNamara, Jennifer Willer, Cristen Roberts, J. Scott BMC Med Genomics Research Article BACKGROUND: Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated. METHODS: We exome sequenced 240 cases with thoracic aortic dissection and 258 controls, then examined 11 aortopathy genes. Pathogenic variants in 6 aortopathy genes (COL3A1, FBN1, LOX, PRKG1, SMAD3, and TGFBR2) were identified in 26 participants, representing 10.8% of the cohort (26/240). A second research sample was used to validate the initial findings. Mailed letters to participants disclosed that a potentially disease causing DNA alteration had been identified (neither the gene nor variant was disclosed). Participants were offered clinical genetic counseling and confirmatory genetic testing in a CLIA laboratory. RESULTS: Excluding 6 participants who were deceased or lost to follow-up, 20 participants received the disclosure letter, 10 of whom proceeded with genetic counseling, confirmatory genetic testing, and enrolled in a survey study. Participants reported satisfaction with the letter (4.2 ± 0.7) and genetic counseling (4.4 ± 0.4; [out of 5, respectively]). The psychosocial impact was characterized by low decisional regret (11.5 ± 11.6) and distress (16.0 ± 4.2, [out of 100, respectively]). The average cost for 26 participants was $400, including validation and sending letters. The average cost for those who received genetic counseling and CLIA laboratory confirmation was $605. CONCLUSIONS: Participants were satisfied with the return of clinically significant biobank genetic results and CLIA laboratory testing; however, the process required significant time and resources. These findings illustrate the trade-offs involved for researchers considering returning research genetic results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-021-00902-5. BioMed Central 2021-03-01 /pmc/articles/PMC7923508/ /pubmed/33648514 http://dx.doi.org/10.1186/s12920-021-00902-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Beil, Adelyn Hornsby, Whitney Uhlmann, Wendy R. Aatre, Rajani Arscott, Patricia Wolford, Brooke Eagle, Kim A. Yang, Bo McNamara, Jennifer Willer, Cristen Roberts, J. Scott Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants |
title | Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants |
title_full | Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants |
title_fullStr | Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants |
title_full_unstemmed | Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants |
title_short | Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants |
title_sort | disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923508/ https://www.ncbi.nlm.nih.gov/pubmed/33648514 http://dx.doi.org/10.1186/s12920-021-00902-5 |
work_keys_str_mv | AT beiladelyn disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT hornsbywhitney disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT uhlmannwendyr disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT aatrerajani disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT arscottpatricia disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT wolfordbrooke disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT eaglekima disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT yangbo disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT mcnamarajennifer disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT willercristen disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants AT robertsjscott disclosureofclinicallyactionablegeneticvariantstothoracicaorticdissectionbiobankparticipants |